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Marc S. WilliamsAbstract
The translational pipeline for genomic medicine has been well defined. However, as with any rapidly changing
technology, innovations are difficult to predict leading to the potential to disrupt anticipated translation. Examples
of potential disruptors such as laboratory-developed tests, direct-to-consumer testing, and patient-centered research
are presented. Awareness of the disruptive nature of innovative approaches is necessary if these innovations are to
be incorporated into current practice.
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researchIn 2011, the National Human Genome Research Insti-
tute (NHGRI) released its new strategic plan [1]. This
plan included an emphasis on the implementation of
genomic medicine in the clinic. The strategic plan has
guided the NHGRI’s funding of several projects such as
the electronic Medical Records and Genomics
(eMERGE) and Implementing Genomics in Practice (IG-
NITE) networks that include implementation as part of
the project goals [2]. Implementation represents the end
of a translational pipeline that starts with discovery re-
search, proceeds through candidate health applications
and translation into practice recommendations and
guidelines to full implementation that results in measur-
able improvement in health outcomes [3]. The current
organization of research and attendant resources as-
sumes that the translation pipeline is the only way for
genomic medicine to move into practice. This discounts
the possibility that outside factors may impact and po-
tentially disrupt this pipeline. This commentary will
present current examples and explore their potential for
disruption.What is disruption?
Disruption, according to the dictionary, means some-
thing “radically different” or “upsetting.” However, dis-
ruption as used in business refers to an innovation thatCorrespondence: mswilliams1@geisinger.edu
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transformation of the industry. The example frequently
used is computers. In the 1970s, computers were large,
mainframe units that were expensive and only available
to large businesses or government entities. A handful of
companies like International Business Machines (IBM)
and Control Data controlled the industry and were very
successful. When the first personal computers were in-
troduced, they were significantly less powerful than the
mainframes and were of little interest to either the exist-
ing computer companies or their clients. However,
putting low-cost computers into the hands of large num-
bers of people democratized the industry and allowed
rapid innovation that in 10 years put all of the large
computer companies out of business. The exception was
IBM which created an entirely separate business unit de-
voted to personal computers in recognition that existing
entities are unlikely to be able to adapt to the disruptive
technology.Disruption in genomics
Genetic testing in the clinic
One the first disruptions to the translation pipeline in-
volved clinical genetic tests. In contrast to medications
that must go through a formal approval process, in the
United States (US), laboratory tests can come to the
market with little regulatory oversight. Rather than fol-
lowing the translational process to develop evidence of
improved health outcomes prior to introduction to thee distributed under the terms of the Creative Commons Attribution License
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clinical validity or disease/gene associations. In some
cases, little evidence exists regarding analytic test per-
formance. The vast majority of clinical genetic tests have
come to market through this way. Much has been writ-
ten about the lack of incentives and reimbursement for
test developers to generate evidence of utility [4] which
has led to consideration of a regulatory framework to
drive tests back through the pipeline so that evidence of
utility can be confirmed. This is fraught with challenges
as well as concerns about how adaptable a regulatory
framework will be in a field where the technical ad-
vances take place at such a rapid pace [5].
Direct-to-consumer genetics
Almost 10 years ago, several direct-to-consumer genetic
testing companies appeared. These offerings exhibited
many of the hallmarks of a disruptive innovation. They
were provided outside the usual medical infrastructure
at a cost that was significantly less expensive than clinic-
ally available tests. The tests themselves offered less util-
ity with much of the information provided not relevant
to health. Bypassing the physician caused a considerable
amount of consternation in both the medical and ethics
communities. All but one of the companies disappeared
from the market relatively quickly. Reasons for this in-
cluded the lack of perceived utility, a price point that
exceeded the consumer’s willingness to pay and inability
to realize a sustainable business model—factors that ap-
pear to have been more significant than the ethical con-
cerns. The remaining company, 23andMe has managed
to remain in the market despite running afoul of the US
Food and Drug Administration. Outside of a larger cap-
ital commitment, 23andMe has pioneered several inno-
vations that have the potential to alter the translational
pipeline. 23andMe participants are offered the opportun-
ity to complete a variety of surveys that have led to an
increasingly rich resource of participant entered data.
This is being used to power novel research methodolo-
gies. In partnership with other organizations around
Parkinson’s disease, the database was used to discover
six new susceptibility loci for Parkinson’s disease [6].
The company is currently participating in 230 different
research studies. If this model proves successful through
the development of innovative methods that allow more
research to be done at a lower cost, this could signifi-
cantly alter the approach of traditional research funders.
Patients take charge
To this point, the scientific research agenda has been de-
termined by the investigators and funding agencies.
While this has resulted in important progress, the lack
of involvement of patients as anything other than partic-
ipants in the research has arguably impacted theimplementation of research results given that some
researcher-defined outcomes are not considered relevant
by patients. In addition, many disorders have had little
research done as they have not been prioritized by the
scientists and funders. The advent of social media and
the internet has allowed patients to begin to aggregate.
Initially, the intent of the groups was to connect patients
and families to share information and provide support.
However, it was soon recognized that these groups pro-
vided an opportunity to research these conditions. This
has been particularly fruitful in ultra-rare genetic dis-
eases. However, this model still depended on identifying
academic researchers and traditional funding sources
which were not always available.
The first large scale effort that leveraged the internet
and social media was PatientsLikeMe™. Founded in 2004,
PatientsLikeMe™ is a patient-powered research network.
Originally focused on amyotrophic lateral sclerosis, (ALS),
PatientsLikeMe™ has expanded to over 2000 different dis-
orders. Using an online platform, PatientsLikeMe™ collects
longitudinal patient-supplied data across a wide range of
parameters including symptom severity, triggers, and re-
sponse to therapies. An online data sharing platform al-
lows rapid dissemination of the submitted information,
and a search engine provides information about clinical
trials throughout the world. PatientsLikeMe™ maintains
an internal staff of researchers. A recent demonstration of
the disruptive potential of this resource involved ALS and
lithium. The results of a small study suggested that lith-
ium might slow the progression of the disease. Many ALS
patients began using lithium off-label, and a subset of
these regularly entered data in the PatientsLikeMe™. In
just 9 months, using the self-reported data of nearly 350
ALS patients PatientsLikeMe™ demonstrated that lithium
did not slow the progress of the disease [7]. While much
remains to be learned about the role and robustness of
this type of research, it is clear that there is no other re-
search entity at present that could have conducted this
study at the cost and within the timeframe in which it was
performed. A recent editorial examined the potential
impact of this as a disruptor of research [8]. Of more con-
cern to traditional research are reports that ALS partici-
pants in double-blinded prospective randomized controlled
trials shared information on their clinical response to
these sites effectively unblinding the arms [9]. As one
affected patient stated, “We simply don’t have time to
wait for the results of ‘clinical trials.’ Our life spans are
much shorter than the ‘Food and Drug Administration’
approval process.” The impact on the research findings
is yet to be studied [10].
In some ways, the impact of these patient-centered ef-
forts has already achieved a significant impact on re-
search funding. The Affordable Care Act created a new
funding organization, the Patient-Centered Outcomes
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ing principles, a commitment to involving patients both
as scientific partners and as part of the review process.
Recently, a large infrastructure funding opportunity from
PCORI called PCORnet is funding up to 22 Patient-
Powered Research Networks (PPRNs). These PPRNs “…
comprise patients and/or caregivers who are motivated to
build an ideal network and play an active role in patient-
centered comparative effectiveness research (CER)” [11].
PCORI is facilitating the interaction between these PPRNs,
and traditional investigator lead Clinical Data Research
Networks to create a new model for network-based health
care research.
This model is emerging in genomic medicine. Geno-
meConnect is a patient-powered registry that is using
patient- and family-entered data to gather rich informa-
tion on a variety of genetic conditions. This uses a fully
consented model for the research using the data, which
is de-identified for the protection of the data contribu-
tors. Genetic test report results are uploaded and associ-
ated with the clinical data to facilitate research into the
phenotypes associated with specific genetic variants.
This project is now receiving funding through the Na-
tional Institutes of Health’s (NIH) Clinical Genome Re-
source project, one of the first examples of a traditional
research funder studying the role and impact of patient-
and family-entered data to enhance a publicly available
genomic resource. While still early, one project, Simons
VIP which is studying the genetic causes of autism en-
rolled over 400 patients and families in 2014. Four out of
five of the registrants indicated an interest in participating
in research and therapeutic trials. Genetics is also repre-
sented in the PCORI PPRNs as three of the funded net-
works are based around a genetic disease with one of the
three using GenomeConnect for data contribution [12].
Support for this as an emerging model came from the
recent NIH Precision Medicine stakeholder conference
where one the strongest recommendations to come out
of the meeting was the need to involve patients not only
as participants but as partners in designing and execut-
ing the project [13].
Conclusion
There are compelling reasons why a robust translational
pipeline for genomic medicine is desirable. However, in
a field of rapidly changing technology and knowledge,
innovation may result in translational pathways that cir-
cumvent and disrupt the assumed pipeline. While this
may not be entirely predictable or preventable, awareness
of this potential may allow for incorporation of some of
these innovations in current programs as is seen in some
of the examples provided. Ultimately, this has the poten-
tial to increase the speed and value of the translation of
genomic medicine into practice.Competing interests
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